大韓民国での分子標的治療に最適なクリニックと費用をご発見ください2026

South Korea offers extensive targeted therapy for common cancers like lung, breast, and colorectal but does not cover every type. Availability depends on specific genetic mutations identified through NGS testing. Major institutions like Samsung Medical Center and Severance Hospital provide advanced drugs for cases with approved biomarkers.

• Available cancers: Targeted drugs treat lung, breast, colorectal, and specific blood cancers.
• Genetic testing: Routine Next-Generation Sequencing (NGS) panels identify eligible mutations for matched therapies.
• Lung cancer: EGFR inhibitors like osimertinib are widely accessible for qualified patients.
• Clinic credentials: Top centers hold JCI and Korea Institute for Healthcare Accreditation (KOIHA) certifications.

Bookimed Expert Insight: While targeted therapy costs start at $5,500, real-world value comes from South Korea’s rapid drug approval cycle. Samsung Medical Center and Seoul National University Hospital often provide access to new therapies years before other regions. This makes Korea a strategic choice for patients seeking the latest FDA-approved molecules that are not yet regional standards.

Patient Consensus: Patients emphasize getting NGS biomarker testing early at major hospitals to unlock treatment options. Many travelers note that while drugs for common mutations are accessible, off-label treatments for rare cases remain expensive without local insurance.

South Korea's top hospitals for targeted therapy include Samsung Medical Center, Severance Hospital, and Seoul National University Hospital. These institutions distinguish themselves through high-volume genomic analysis, Next-Generation Sequencing, and multidisciplinary teams that match specific genetic mutations to precise drug regimens for complex cancers.

• Samsung Medical Center: Features a Precision Oncology Center with over 10,000 genomic analysis cases.
• Severance Hospital: Offers 24/7 oncology ICU support and rapid access to advanced immunotherapies.
• Seoul National University: Fully digitalized facility achieving some of the nation's highest cancer success rates.
• Ewha Womans University: Specializes in precision oncology for breast and gynecological cancers with aesthetic focus.

Bookimed Expert Insight: Samsung Medical Center and Seoul National University Hospital serve a combined 3.6 million patients annually. This massive volume allows their specialists to encounter rare genetic mutations more frequently than most Western centers. This deep data pool directly improves the accuracy of their Next-Generation Sequencing panels for therapy matching.

Patient Consensus: Patients value the speed of genomic mapping, which often takes only days. Many suggest requesting Next-Generation Sequencing upfront to ensure the most effective therapy match immediately.

South Korean National Health Insurance (NHI) covers many targeted therapies, typically reducing patient costs to 5% of the total medical bill for reimbursed treatments. Coverage depends on specific drug approval for the patient's cancer type and stage as determined by the Health Insurance Review and Assessment Service (HIRA).

• Co-payment rates: Patients generally pay 5% for reimbursed cancer drugs under the special benefit program.
• Reimbursement list: Approximately 150 targeted agents are currently covered for specific, approved medical indications.
• Non-reimbursed costs: Patients must pay 100% out-of-pocket if a therapy is used off-label or non-listed.
• Approval timeline: Authorization for specific targeted treatments usually takes between 2 to 4 weeks.

Bookimed Expert Insight: While NHI offers significant savings, university hospitals like Severance Hospital or Samsung Medical Center often have higher approval odds for complex cases. These top-tier facilities participate in international clinical trials, providing access to cutting-edge therapies before they reach the official reimbursement list.

Patient Consensus: Patients report that while coverage is generous compared to US costs, the bureaucracy can cause delays. Many recommend bringing detailed genetic reports to speed up the authorization process at major Seoul hospitals.

South Korea accelerates access to targeted drugs through the GIFT (Global Innovative Products on Fast Track) system and the 2025 approval reforms. These pathways prioritize severe or rare diseases. They aim to reduce regulatory review timelines from 420 days to approximately 295 days.

• Regulatory speed: Accelerated pathways like GIFT target drug approval within 90 days for critical illnesses.
• Parallel processing: Companies can apply for reimbursement and marketing authorization simultaneously to reduce wait times.
• Affordability exemptions: Drugs for life-threatening diseases may bypass economic evaluations if reimbursed in A7 countries.
• Conditional approval: The ministry grants marketing rights based on phase 2 data for oncology treatments.

Bookimed Expert Insight: Samsung Medical Center and Severance Hospital often provide the fastest access through named patient programs. These programs allow patients to receive new drugs 3–6 months before official reimbursement. In some cases, these medications are available at 20–50% of the standard US price.

Patient Consensus: Patients report that the prior approval system through major Seoul hospitals can secure insurance coverage for advanced lung cancer drugs like Tagrisso within just a few days.

The Ministry of Food and Drug Safety (MFDS) supervises targeted therapy in the Republic of Korea under the Pharmaceutical Affairs Act. This framework distinguishes between small-molecule drugs and advanced biological products. Specialized systems like the GIFT program and ARMAB Act accelerate access to innovative cancer treatments.

• Core legislation: The Pharmaceutical Affairs Act regulates manufacturing, distribution, and standard drug approvals.
• Advanced biologics: The ARMAB Act provides specialized safety frameworks for cell and gene therapies.
• Fast-track approval: The GIFT program shortens approval timelines by 25% for life-threatening diseases.
• Market access: Risk Sharing Agreements (RSA) manage clinical uncertainty between developers and insurance authorities.

Bookimed Expert Insight: Clinical data from top-tier institutions like Samsung Medical Center and Seoul National University Hospital shows a unique regulatory advantage. These major academic centers often navigate the MFDS approval process for targeted therapies 6 to 12 months faster than the FDA. This speed allows patients to access newer Japanese or European therapies before they reach the US market.

Patient Consensus: Patients emphasize that MFDS approval does not guarantee insurance coverage. Many coordinate with hospital networks to manage out-of-pocket costs for non-reimbursed agents through pharmaceutical assistance programs.